Specific Killing of Human Melanoma Cells by 125l-Labeled 9.2.27 Monoclonal Antibody

Cancer Research

Volumn 45, Issue 10, 1985, Pages 5080-5087

  Lindmo, Tore ^a   Boven, Epie ^a   Bunn, Paul A ^a   Mitchell, James B ^a   Morstyn, George ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 125; RADIOISOTOPE;

CELL LINE; CLONOGENIC ASSAY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL; THERAPY; TUMOR CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE; CELL SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MELANOMA;

EID: 0022357916     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Baldwin, R. W., and Pimm, M. V. Antitumor monocolonal antibodies for radioimmunodetection of tumors and drug targeting. Cancer Metastasis Rev., 2:89–106,1983.
2. Order, S. E. The history and progress of serologic immunotherapy and radiodiagnosis. Radiology, 118:219–223,1976.
3. Order, S. E. Monoclonal antibodies: potential role in radiation therapy and oncology. Int. J. Radiat. Oncol. Biol. Phys., 8:1193–1201,1982.
4. Pressman, D. The development and use of radiolabeled antitumor antibodies. Cancer Res., 40: 2960–2964,1980.
5. Cotombatti, M., Cofombatti, A., Blythman, H. E., and Bron, C. Thy 1.2+ leukemia cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates. J. Natl. Cancer Inst, 72:1095–1099,1984.
6. Hashimoto. N., Takatsu, K., Masuho, Y., Kishida. K., Hara, T., and Hamaoka, T. Selective elimination of a B cell subset having acceptor site(s) for T cell-replacing factor (TRF) with biotirtylated antibody to the acceptor site(s) and avidin-ricin A-chain conjugate. J. Immunol., 732; 129–135.1984.
7. Bernhard. M. I., Hwang, K. M., Foon, K. A., Keenan, A. M., Kessler, R. M., Frincke. J. M., Tallam. D. J., Hanna. M. G., Jr., Peters. L. and Oldham. R. K. Localization of 111In- and 125I-Iabeledabe monoclonal antibody in guinea pigs bearing line 10 hepatocarcinoma tumors. Cancer Res., 43:4429–4433.1983.
8. Houston, L. L., Nowinski. R. C. and Bernstein, I. D. Specific in vivo localization of monoclonal antibodies dfrected against the Thy 1.1 antigen. J. Immunol., 125: 837–843,1980.
9. Mach, J. P., Chatal, J. F., Lumbroso, J. D., Buchegger, F., Fomi, M., Ritschard, J., Berche. C., Douillard. J. Y., Carrel. S., Herlyn, M., Steplewski, Z., and Koprowski, H. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res., 43:5593–5600,1983.
10. Moshakis, V., Mcllhinney, R. A. J., Raghavan, D., and Neville. A. M. Localization of human tumor xenografts after i.v. administration of radiolabelled monoclonal antibodies. Br. J. Cancer, 44:91–99,1981.
11. Scheinberg, D. A., and Strand. M. Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res., 42:44–49.1982.
12. Zalcberg. J. R., Thompson, C. H., Lichtenstein, M., Andrews, J., and McKenzie, I. F. C. Localization of human colorectal tumor xenografts in the nude mouse with the use of radiolabeled monoclonal antibody. J. Natl. Cancer Inst., 71: 801–808.1983.
13. Carrasquillo, J. A., Krohn. K. A., Beaumier. P., McGuffin. R. W., Brown, J. P., Hellstrom, K. E., Helstrom, I., and Larson, S. M. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat. Rep., 68: 317–328,1984.
14. Ettinger, D. S., Dragon, L. H., Klein, J., Sgagias, M., and Order, S. E. Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer a case report. Cancer Treat. Rep., 63:131–134,1979.
15. Ettinger. D. S., Order. S. E., Wharam, M. D., Parker, M. K., Klein. J. L. and Leichner, P. K. Phase Ml study of isotopic immunoglobulin therapy for primary liver cancer. Cancer Treat. Rep., 66:289–297,1982.
16. Goldenberg, D. M., Gaffar, S. A., Bennett, S. J., and Beach, J. L. Experimental radioimmunotherapy of a xenografted humeri colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res., 47; 4354–4360.1981.
17. Larson, S. M., CarrasquiHo, J. A., Krohn, K. A., Brown, J. P., McGuffin. R. W., Ferens, J. M., Graham. M. M., Hid. L. D., Beaumier, P. L., Hellstrdm, K. E., and Hellstrom. I. Localization of 131l labeled p97 specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest., 72:2101–2114, 1983.
18. Order, S.E., Klein, J. L.,Ettingerer,D.,Alderson, P., Siegelman, S., and Leichner, P. Phase I–II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. Int. J. Radiat. Oncol. Biol. Phys., 6: 703–710. 1980.
19. Order, S.E., Klein, J. L., Ettinger, D., Alderson, P., Siegelman.S., and Leichner. P. Use of isotopic immunoglobulin in therapy. Cancer Res., 40: 3001–3007. 1980.
20. Zalcberg. J. R., Thompson, C. H., Lichtenstein, M., and McKenzie. I. F. C. Tumor irnmunotherapy in the mouse with the use of 131Mabeted monoclonal antibodies. J. Natl. Cancer Inst., 72: 697–704,1984.
21. Waiters, R. L., Hofer, K. G., Harris, C. R., and Smith, J. M. Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr. Top. Radiat. Res. Q., 12:389–407,1977.
22. Strand, M., Scheinberg, D. A., Gansow, O. A., and Friedman, A. M. Monoclonal antibody conjugates for diagnostic imaging and therapy, in: B. D. Boss, R. Langman, I. Trowbridge, and R. Dulbecco (eds.). Monoclonal Antibodies and Cancer, pp. 125–131. New York: Academic press. 1983.
23. Vaughan, A. T. M., Bateman, W. J., Brown. G., and Cowan. J. The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies-l. Int. J. Nucl. Med. Biol., 9; 167–171,1982.
24. Morstyn, G., Miller, R., Russo, A., and Mitchell, J. 131-Iodine conjugated antibody cell ki enhanced by bromdeoxyuridine. Int. J. Radiat. Oncol. Biol. Phys., 10:1437–1440,1984.
25. Morgan, A. C. Galloway. D. R., and Reisfeld, R. A. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma, 1:17–36,1981.
26. Bumol. T. F., and Reisfeld, R. A. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc. Natl. Acad. Sci. USA, 79:1245–1249,1982.
27. Hunter, W. M., and Greenwood, F. C. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature (Lond.), 194; 495–496,1962.
28. Lindmo, T., Boven, E., Cuttitta. F., Fedorko, J., and Bunn. P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72:77–89,1984.
29. Lindmo, T., Davies, C., Fodstad, ø., and Morgan, A. C. Stable quantitative differences of antigen expression in human melanoma cells isolated by flow cytometric cell sorting. Int. J. Cancer. 34:507–512,1984.
30. Carney, D. N., Mitchel, J. B., and Kinsella, T. J. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res., 43:2806–2811, 1983.
31. Cuttitta, F., Rosen. S., Gazdar, A. F., and Minna, J. D. Monoclonal antibodies that demonstrate specificity for several types of human lung cancer. Proc. Natl. Acad. Sci. USA, 78:4591–4595.1981.
32. Krishan, A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol., 66:188–193.1975.
33. Dillman. L. T., and Von der Lage. F. C. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. MIRD Pamphlet No. 10. p. 71. New York: Society of Nuclear Medicine. 1975.
34. Ellett, W. H., and Humes, R. M. Absorbed fractions for small volumes containing photon-emitting radioactivity. MIRD Pamphlet No. 8. J. Nucl. Med., 12 (Suppl. 5): 25–32,1971.
35. Smith, E. M., Harris. C. C., and Rohrer, R. H. Calculation of local energy deposition due to electron capture and internal conversion. J. Nucl. Med., 7: 23–31,1965.
36. Bonn, B. High-sensitivity cytofluorometric quantitation of lectin and hormone binding to surfaces of living cells. Exp. Cell Res., 103; 39–46.1976.
37. Boven, E., Lindmo, T., Mitchell, J., and Bunn. P. Radioimmunotherapy of malignant human T cell lines with 125I-T101 monoclonal antibody. Proc. Am. Assoc. Cancer Res., 26:289,1985.
38. Bloomer, W. D., McLaughlin, W. H., Weichselbaum, R. R., Tonnesen, G. L. Heflman, S., Seitz, D. E., Hanson, R. N., Adelstein, S. J., Rosner, A. L., Burstein, N. A., Nove, J. J., and Little, J. B. lodine-125-labelled tamoxifen is differential cytotoxic to cells containing oestrogen receptors. Int. J. Radiat. Biol., 38:197–202,1980.
39. Oldham, R. K., Foon, K. A., Morgan, A. C., Woodhouse. C. S., Schroff, R. W., Abrams, P. G., Fer, M., Schoenberger, C. S., Farrel, M., Kimball, E., and Sherwin, S. A. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J. Cin. Oncol., 2:1235–1244.1984.
40. Schroff. R. W., Farrel, M. M., Klein, R. A., Oldham, R. K., and Foon, K. A. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J. Immunol., 133; 1641–1648,1984.
41. Shawler, D. L., Miceli, M. C. Wormsley, S. B., Royston, I., and Dilman. R. O. Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res., 44: 5921–5927,1984.
42. Bunn, P. A., Jr., CarrasquiHo. J. A., Keenan, A. M., Schroff, R. W., Foon, K. A., Hsu, S. M., Gazdar, A. F., Reynolds, J. C., Perentesis, P., and Larson, S. M. Imaging of T-cell lymphoma by radiolabeled monoclonal antibody. Lancet, 2:1219–1221,1984.